Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2000-09-01
2004-09-28
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S195110, C424S184100, C424S197110, C424S236100, C424S192100, C536S123000, C528S332000
Reexamination Certificate
active
06797275
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to methods of using conjugates of the capsular polysaccharide of
Salmonella typhi
, Vi, bound to the carrier
Pseudomonas aeruginosa
recombinant exoprotein A (rEPA) with a carboxylic acid dihydrazide linker, preferably an adipic acid dihydrazide (ADH) linker, and compositions of these conjugates, for eliciting serum antibody responses in humans, including responses which provide protection against, or reduce the severity of,
S. typhi
bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which are useful to prevent and/or treat illnesses caused by
S. typhi.
BACKGROUND
In developing countries, typhoid fever is common, serious, and increasingly difficult to treat because of resistance of the bacillus to antibiotics. [24, 63-66]. For example, more than 80% of
Salmonella typhi
from the Mekong Delta region of Vietnam are resistant to chloramphenicol and to ampicillin and even more expensive antibiotics such as ciprofloxacin. Typhoid fever has been thought of as a disease of mostly older children and young adults. In children less than 5 years of age, typhoid fever was often unrecognized due to atypical clinical symptoms, difficulties in drawing blood and less-than-optimal culture media. [66-69]. Similar to recent findings in other parts of Southeast Asia [70-72], a preliminary survey in 3 communes of the Dong Thap province of Vietnam showed that the annual attack rate of typhoid fever was highest among children less than 15 years of age: it was 413/100,000 in this age group and 358/100,000 for 2 to 4 year-olds. [73].
Unfortunately, it is unlikely that safe drinking water and foodstuffs will be available in many developing countries, especially in rural areas, in the near future. [24, 66, 74]. Control of typhoid fever by routine vaccination, especially in countries that endure high endemic rates of typhoid fever, has not been adopted because of the limitations of the three licensed vaccines (parenteral inactivated cellular vaccines, oral attenuated
S. typhi
Ty21a, and parenteral Vi polysaccharide). These vaccines confer only approximately 70% immunity to older children and adults but do not protect young children. [24, 1, 30, 75, 76].
Orally administered attenuated
S. typhi
Ty21a requires at least 3 doses, has a low rate of efficacy in areas with a high rate of typhoid fever and in travelers from developed countries and is not immunogenic in young children. Neither the protective antigens nor the vaccine-induced host immune responses have been identified which hinders improvement of the Ty21a vaccine.
Although effective in areas with high rates of typhoid fever, killed whole cell parenteral vaccines elicit a high rate of adverse reactions and have not been shown to be effective in young children. In 1952, Landy concluded that the protective antigen of cellular vaccines is the capsular polysaccharide (Vi) of
S. typhi.
In two randomized, double-blinded, vaccine-controlled clinical trials, one injection of Vi induced about 70% efficacy in ≧5 year-olds in the Kathmandu Valley of Nepal and in the Eastern Transvaal region of the Republic of South Africa: these regions had a high rate of endemic typhoid (0.4 to 1% per year) [1]. Recently, similar results were obtained by the Lanzhou Institute of Biologic Products in the People's Republic of China [manuscript in preparation]. Vi is easily standardized. The World Health Organization has published requirements for Vi polysaccharide typhoid vaccine and this product is licensed in about 50 countries including the United States [59,60]. But Vi induces only short-lived antibody responses in children two to five years of age and does not elicit protective levels in children less than two years old: in adults, reinjection restores the level of vaccine-induced anti-Vi but does not elicit a booster response. These age-related and T-independent immunologic properties are similar to most other polysaccharide vaccines.
We proposed that it is the vaccine-induced serum IgG anti-Vi that confers immunity. Accordingly, the level of serum IgG anti-Vi should predict the efficacy of Vi vaccine. In order to improve its immunogenicity, Vi was conjugated to proteins using SPDP [51, 52, 54, 62]. The protein carriers for the SPDP linked conjugates included cholera toxin (CT), tetanus toxoid (TT), the B subunit of the heat-labile cholera-like enterotoxin (LT-B) of
Escherichia coli
and the recombinant exoprotein A (rEPA) of
Pseudomonas aeruginosa
(i.e., the nontoxic recombinant form of exotoxin from
Pseudomonas aeruginosa
(ETA) cloned into and secreted by
E. coli
). [Id.]. Recently, we employed another synthesis that treated rEPA with adipic acid dihydrazide (ADH) and bound the hydrazide derivative of rEPA (rEPA-AH) to Vi with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) [31]. The safety and immunogenicity of the Vi-rEPA conjugates prepared either with N-succinimidyl-3-(2-pyridyl dithio) propionate (SPDP, Vi-rEPA
I
) or adipic acid dihydrazide (ADH, Vi-rEPA
II
) as linkers, were compared sequentially in adults, 5-14 year-olds and then 2-4 year olds in Vietnam. The data set forth in Example 5 herein demonstrate that the resultant conjugate (Vi-rEPA) both enhanced the immunogenicity of and conferred T-cell dependent properties to Vi. Vi-rEPA elicited a booster response in 2 to 4 year-olds with IgG anti-Vi levels approximately 3 times higher than those elicited by Vi in 5 to 14 year-olds. None of the vaccinees had a temperature >38.5° C. or swelling >2.5 cm following injection. On the basis of these results, we initiated a double-blinded placebo-controlled randomized trial to determine the efficacy of Vi-rEPA in 2 to 5 year-old Vietnamese children, an age group for which there is yet no effective typhoid vaccine. The results of that efficacy trial are set forth in Example 6 herein.
BRIEF DESCRIPTION OF THE INVENTION
It is an object of the invention to provide methods of using conjugates of the capsular polysaccharide of
Salmonella typhi
(Vi) bound to the carrier rEPA (as carrier protein) with a carboxylic acid dihydrazide linker, preferably an adipic acid dihydrazide (ADH) linker, and/or compositions thereof, for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly, it is an object of the invention to provide methods of using such conjugates, and/or compositions thereof, to induce serum antibodies against the capsular polysaccharide of
S. typhi
, called Vi. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which are useful to prevent typhoid fever.
It is also an object of the invention to provide antibodies which immunoreact with the Vi polysaccharide of
S. typhi
and/or the rEPA carrier, that are induced by these conjugates and/or compositions thereof. Such antibodies may be isolated, or may be provided in the form of serum containing these antibodies.
It is also an object of the invention to provide a method for the treatment or prevention of
S. typhi
infection in a mammal, by administration of compositions containing the antibodies of the invention, or serum containing the antibodies of the invention.
The invention also provides methods and kits for identifying, detecting, and/or diagnosing
S. typhi
infection or colonization using the antibodies which immunoreact with the Vi polysaccharide of
S. typhi
. The invention also relates to methods and kits for identifying, detecting and/or diagnosing the presence of
P. aeruginosa
and/or
P. aeruginosa
exotoxin A (ETA).
The Vi-rEPA
II
conjugates of this invention induce a strong initial IgG antibody response in humans. In this respect, they have a significant advantage over the Vi-rEPA
I
conjugates.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides methods of using conjugates of an
S
Kossaczka Zuzana
Robbins John B.
Szu Shousun Chen
Klarquist & Sparkman, LLP
Portner Ginny Allen
Smith Lynette R. F.
The United States of America as represented by the Department of
LandOfFree
Method of immunizing humans against Salmonella typhi using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of immunizing humans against Salmonella typhi using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of immunizing humans against Salmonella typhi using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3252142